BME$GRFS
Grifols SA · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Grifols SA reported Q1 2026 results with revenue growth driven by Biopharma and IG franchise strength.
Grifols reported total revenue of €1.7 billion in Q1 2026, up 3.3% on a constant currency basis. Net profit rose 21.9% to €73 million. Performance was aligned with plan, supported by Biopharma growth of 6.8% cc, with IG up 15.3% cc.
- Revenue reached €1.7 billion, +3.3% cc YoY, driven by Biopharma (+6.8% cc) and IG franchise (+15.3% cc).
- Net profit increased 21.9% to €73 million.
- Adjusted EBITDA was €381 million with stable margin of 22.4%.
- Free cash flow pre-M&A improved to -€8 million; leverage at 4.3x with liquidity of €1.573 billion.
Headline financials
Revenue & EPS history
Grifols · Revenue · Quarterly
€1.93B
Forward guidance
Q1 performance aligned with expectations and supports full-year 2026 guidance.
Tailwinds
- On track to achieve 2026 objectives.
- Margin expansion expected from gross margin improvements and plasma optimization.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+38.2%
Avg return
Earnings day
-0.3%
Avg return
5 days after
-0.2%
Avg return
30 days after
22%
12 / 55 earnings
Positive
+1950.4%
Q4 2010
Best reaction
-8.9%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | — | — | — | |
| Q2 2024 | +3.5% | +11.6% | +22.8% | |
| Q1 2024 | +0.7% | +1.4% | +10.5% | |
| Q4 2024 | -3.8% | -2.3% | +17.7% | |
| Q3 2023 | +0.0% | -5.6% | -14.0% | |
| Q2 2023 | +2.7% | +1.5% | +17.1% | |
| Q4 2022 | +0.0% | -0.5% | +14.1% | |
| Q1 2023 | +0.0% | -4.4% | -0.1% | |
| Q3 2022 | +0.0% | +10.3% | +5.5% | |
| Q2 2022 | -7.5% | -21.8% | -24.9% | |
| Q1 2022 | -0.0% | +0.3% | -9.1% | |
| Q3 2021 | -5.1% | -0.1% | -12.1% | |
| Q2 2021 | +4.6% | -0.6% | -6.5% | |
| Q1 2021 | -0.2% | +5.8% | -2.7% | |
| Q4 2020 | +0.0% | -5.3% | +3.9% | |
| Q3 2020 | +0.0% | +8.1% | +7.1% | |
| Q2 2020 | +0.0% | -1.6% | -17.2% | |
| Q1 2020 | +0.4% | -3.6% | -1.0% | |
| Q4 2019 | -8.9% | -7.5% | -15.4% | |
| Q3 2019 | +0.0% | +4.5% | +7.0% | |
| Q2 2019 | +0.0% | -3.7% | -5.6% | |
| Q1 2019 | +0.0% | -4.0% | -2.5% | |
| Q4 2018 | -4.4% | +0.8% | +3.0% | |
| Q3 2018 | +0.0% | +0.0% | -8.7% | |
| Q2 2018 | +0.0% | -1.2% | -1.1% | |
| Q1 2018 | +0.0% | +6.6% | +8.1% | |
| Q4 2017 | +0.0% | -5.0% | -5.2% | |
| Q3 2017 | +8.0% | +0.3% | -4.3% | |
| Q2 2017 | +0.0% | +3.6% | +2.1% | |
| Q1 2017 | +0.0% | -2.1% | -1.0% | |
| Q4 2016 | +8.2% | +3.0% | +8.9% | |
| Q3 2016 | +0.0% | -0.8% | -8.3% | |
| Q2 2016 | +0.0% | +4.1% | +6.6% | |
| Q4 2015 | +0.0% | — | — | |
| Q1 2016 | +0.0% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q4 2014 | +0.0% | — | — | |
| Q1 2015 | +0.0% | — | — | |
| Q3 2014 | +0.0% | — | — | |
| Q2 2014 | -2.7% | — | — | |
| Q4 2013 | +0.7% | — | — | |
| Q1 2014 | -0.1% | — | — | |
| Q3 2013 | +0.0% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q4 2012 | +0.0% | — | — | |
| Q1 2013 | +0.0% | — | — | |
| Q3 2012 | +152.0% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q4 2010 | +1950.4% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q3 2010 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro